<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: No published data are available on the risk of further <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">neoplastic progression</z:e> in Barrett's patients stratified by baseline <z:mpath ids='MPATH_589'>dysplasia</z:mpath> status </plain></SENT>
<SENT sid="1" pm="."><plain>Our aims were to estimate and compare the risk of progression to high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> or <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in groups of Barrett's patients stratified by baseline <z:mpath ids='MPATH_589'>dysplasia</z:mpath> status </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Consecutive Barrett's cases from 1988-2002 were identified via pathology databases in a regional VA health-care system and medical record data were abstracted </plain></SENT>
<SENT sid="3" pm="."><plain>The risk of progression to high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> or <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> was measured and compared in cases with versus without low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> within 1 yr of index endoscopy using survival analysis </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: A total of 575 Barrett's cases had 2,775 patient-years of follow-up </plain></SENT>
<SENT sid="5" pm="."><plain>There were 13 incident cases of high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and two of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>The crude rate of high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> or <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> was 1 of 78 patient-years for those with baseline <z:mpath ids='MPATH_589'>dysplasia</z:mpath> versus 1 of 278 patient-years for those without (p= 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>One case of high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> in each group underwent successful therapy </plain></SENT>
<SENT sid="8" pm="."><plain>One incident <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> case underwent successful resection and the other was unresectable </plain></SENT>
<SENT sid="9" pm="."><plain>Two cases with high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> later developed <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, one died postoperatively, the other was unresectable </plain></SENT>
<SENT sid="10" pm="."><plain>When these two cases were included (total of four <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>), the crude rate of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> was 1 of 274 patient-years for those with baseline <z:mpath ids='MPATH_589'>dysplasia</z:mpath> versus 1 of 1,114 patient-years for those without </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: In a large cohort study of Barrett's, incident <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> was uncommon </plain></SENT>
<SENT sid="12" pm="."><plain>The rate of progression to high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> or <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> was significantly higher in those with baseline low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
<SENT sid="13" pm="."><plain>These data may warrant reevaluation of current Barrett's surveillance strategies </plain></SENT>
</text></document>